Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.72 |
| ▸ | RAB9A | P51151 | 9/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673320 | 0.98 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8396558 | 0.98 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL307051 | 0.98 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23594174 | 0.98 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5168314 | 0.98 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6928283 | 0.96 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3747209 | 0.96 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2316588 | 0.96 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4042448 | 0.94 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL124395 | 0.92 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | claimed |
| EP-3612518-A1 | SMALL MOLECULE INHIBITORS OF BCL-2-ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | National University of Singapore (SG) | 2020-02-26 | — | — | EP | claimed |
| WO-2018194520-A9 | SMALL MOLECULE INHIBITORS OF BCL-2-ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-10-17 | — | — | WO | claimed |
| WO-2018194520-A1 | SMALL MOLECULE INHIBITORS OF BCL-2-ASSOCIATED DEATH PROMOTER (BAD) PHOSPHORYLATION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-10-25 | — | — | WO | claimed |
| EP-1768960-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-04 | — | — | EP | claimed |
| CN-1867572-A | proteasome inhibitors and methods of use thereof | CEPHALON INC (US) | 2006-11-22 | — | — | CN | claimed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2024261504-A1 | BENZOFURAN-3-CARBOXYLIC ACID AMIDES AND BENZOFURAN-3- CARBONYL-BENZAMIDES, METHOD FOR THEIR PRODUCTION WITH HIGH SELECTIVITY, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PÉCSI TUDOMÁNYEGYETEM (HU) | 2024-12-26 | — | — | WO | disclosed |
| CN-117466799-B | N-substituted phthalic acid diamide preparation method of imine compound | 西北师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-117105963-A | Preparation method for synthesizing aryl silicon compound by iron-catalyzed aryl ether carbon-oxygen bond cleavage and chlorosilane reaction | 西北工业大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2006005486-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| CN-1055920-C | Alkyl benzoylguanidines derivatives | MERCK PATENT GMBH (DE) | 2000-08-30 | — | — | CN | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| CN-1128753-A | Alkyl benzoylguanidines derivatives | MERCK PATENT GMBH (DE) | 1996-08-14 | — | — | CN | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-3879540-A | Methods and cyclopentyl benzamide compositions for producing depressant activity | UNIV TOLEDO | 1975-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | NPC1 357/4885RAB9A 1351/4885SMN1; SMN2 3044/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | NPC1 161/4885RAB9A 1657/4885SMN1; SMN2 962/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | NPC1 123/4885RAB9A 1445/4885SMN1; SMN2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.